

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions and listings of claims in the application:

Claims 1-8 (Canceled)

9. (New) A method of reducing chemokine-mediated migration of leukocytes in an individual suffering from an inflammatory disease or disorder, comprising administering antithrombin III to said individual in an amount sufficient to interact with one or more cellular receptors to effect a blockade of chemokine receptors, and reduce chemokine-mediated migration of leukocytes,

wherein said inflammatory disease or disorder is

a) an oncological disease, a disease accompanying neovascularization, a viral infection, a fibrotic disease or disorder, vasculitis, a granulomatous disease, a degenerative disease of the nervous system, atherosclerosis, gout; or

b) an autoimmune disease, provided that the autoimmune disease is not arthritis, or

c) an allergic disease, provided that the allergic disease or disorder is not asthma.

10. (New) The method of claim 9, wherein the disease or disorder is vasculitis or a granulomatous disease.

11. (New) The method of claim 9, wherein the disease or disorder is an autoimmune disease or disorder.

12. (New) The method of claim 11, wherein the autoimmune disease is systemic lupus erythematosus or pemphigus.

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

13. (New) The method of claim 9, wherein the disease or disorder is a viral infection.
14. (New) The method of claim 13, wherein the viral infection is caused by a human immunodeficiency virus.
15. (New) The method of claim 13, wherein the viral infection involves viral penetration into target cells via chemokine receptors.
16. (New) The method of claim 9, wherein the disease or disorder is an allergy or allergic reaction.
17. (New) The method of claim 16, wherein the allergy or allergic reaction is urticaria or angioedema.
18. (New) The method of claim 16, wherein the allergy or allergic reaction is rhinitis, conjunctivitis, or dermatitis.
19. (New) The method of claim 9, wherein the disease or disorder is a degenerative disease of the nervous system.
20. (New) The method of claim 19, wherein the degenerative disease of the nervous system is Alzheimer's disease.
21. (New) The method of claim 9, wherein the disease or disorder is an oncological disease or disorder.
22. (New) The method of claim 21, wherein the oncological disease or disorder is an inflammatory neoplasia.
23. (New) The method of claim 9, wherein the disease or disorder is a disease or disorder accompanying neovascularization.

24. (New) The method of claim 9, wherein the disease or disorder is atherosclerosis accompanied by a chemokine-mediated infiltration by leukocytes.

25. (New) The method of claim 9, wherein the disease or disorder is gout.

26. (New) The method of claim 9, wherein the disease or disorder is a fibrotic disease or disorder.

27. (New) The method of claim 9, comprising administering antithrombin III in an amount sufficient to reduce interleukin-8-mediated migration of leukocytes.

28. (New) The method of claim 9, wherein said antithrombin III is obtained from plasma or a recombinant or transgenic source.

29. (New) The method of claim 9, wherein said antithrombin III is administered intravenously, subcutaneously, intradermally, intramuscularly, or topically.

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com